Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Watching Globalstar; Traders Circulate Government SmartOne C And SPOT Trace Tracking Devices Request

https://sam.gov/opp/270aef1b0b3a4471a53d9508fb4d8268/view
byBenzinga Newsdesk
January 13, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

https://sam.gov/opp/270aef1b0b3a4471a53d9508fb4d8268/view

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

FDA Accepted Submission of Supplemental New Drug Application for LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

By Charles Gross
August 16, 7:25 AM
AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA in combination with abiraterone and prednisone or prednisolone has been accepted and granted priority review by the U.S.

AZN